Production and characterization of an active single-chain variable fragment antibody recognizing CD25.
暂无分享,去创建一个
Kazuhiro Yoshikawa | Ryuzo Ueda | S. Saga | R. Ueda | H. Muramatsu | K. Yoshikawa | Shigeki Sato | Toshitada Takahashi | Hideki Muramatsu | Takeshi Hayashi | Syuntaro Takasu | Yoichi Kawada | Kazuo Uchida | Toshitada Takahashi | Shinsuke Saga | Shigeki Sato | Syuntaro Takasu | Takeshi Hayashi | Kazuo Uchida | Y. Kawada
[1] S. Tsugane,et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Morrison,et al. Antibody-cytokine fusion proteins for the therapy of cancer. , 2001, Journal of immunological methods.
[3] A. Saven,et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia , 1993 .
[4] V. Georgoulias,et al. Characterization of interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells. , 1994, Leukemia.
[5] T. Fujita,et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.
[6] H. Stein,et al. T-cell growth factor receptor (Tac-antigen) expression in cutaneous lymphoid infiltrates. , 1986, Journal of the American Academy of Dermatology.
[7] T. Waldmann,et al. Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. , 1988, The Journal of biological chemistry.
[8] I. Pastan,et al. Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin. , 1993, Bioconjugate chemistry.
[9] T. Nishiura,et al. Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: Functional and structural characterization , 1990, Blut.
[10] Y. Berdichevsky,et al. Escherichia coli maltose-binding protein as a molecular chaperone for recombinant intracellular cytoplasmic single-chain antibodies. , 2001, Journal of molecular biology.
[11] H. Neu,et al. The release of enzymes from Escherichia coli by osmotic shock and during the formation of spheroplasts. , 1965, The Journal of biological chemistry.
[12] T. Uchiyama,et al. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. , 1989, Blood.
[13] J. Humm,et al. Targeted α particle immunotherapy for myeloid leukemia , 2002 .
[14] W. Blattner,et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. , 1983, The New England journal of medicine.
[15] R. Ueda,et al. Serum Soluble Interleukin‐2 Receptor Levels in Patients with Adult T‐cell Leukemia and Human T‐cell Leukemia/Lymphoma Virus Type‐I Seropositive Healthy Carriers , 1988, Japanese journal of cancer research : Gann.
[16] J. Strauchen,et al. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. , 1987, The American journal of pathology.
[17] W. Blattner,et al. Cytokine induction in HTLV‐I associated myelopathy and adult T‐cell leukemia: Alternate molecular mechanisms underlying retroviral pathogenesis , 1991, Journal of cellular biochemistry.
[18] T. Waldmann,et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin , 1989, Nature.
[19] M. Toda,et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.
[20] G. Pinkus,et al. Specific phenotyping of T-cell proliferations in formalin-fixed paraffin-embedded tissues. Use of antibodies to the T-cell receptor beta F1. , 1990, American journal of clinical pathology.
[21] Sayuri Yamazaki,et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.
[23] M. Mizuno,et al. Production of a Single‐chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor , 2000, Japanese journal of cancer research : Gann.
[24] M. Seto,et al. Two mouse monoclonal antibodies detecting two different epitopes of an activated lymphocyte antigen on adult T-cell leukemia cells. , 1985, Cancer research.
[25] A. Chott,et al. Peripheral T-cell lymphomas: a clinicopathologic study of 75 cases. , 1990, Human pathology.
[26] T. T. Wu,et al. Kabat database of sequences of proteins of immunological interest , 1996 .
[27] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] D. Blayney,et al. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases. , 1987, The American journal of pathology.
[29] T. Waldmann,et al. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. , 1981, Journal of immunology.
[30] T. Tüting,et al. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. , 2001, Cancer research.
[31] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[32] L. Herzenberg,et al. Immunochemistry and molecular immunology , 1996 .
[33] M. Shibuya,et al. Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. , 1996, British Journal of Cancer.
[34] G. Adams,et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.
[35] M. Tsudo,et al. Interleukin‐2 Receptor β‐Chain (p70–75) Expressed on Leukemic Cells from Adult T Cell Leukemia Patients , 1990, Japanese journal of cancer research : Gann.
[36] T. Elliott,et al. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens , 2002, European journal of immunology.
[37] B. Agnarsson,et al. The immunophenotype of reed‐sternberg cells. A study of 50 cases of Hodgkin' disease using fixed frozen tissues , 1989, Cancer.
[38] T. Waldmann,et al. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. , 1981, Journal of immunology.
[39] D. Mason,et al. CD25 Is a Marker for CD4+ Thymocytes That Prevent Autoimmune Diabetes in Rats, But Peripheral T Cells with This Function Are Found in Both CD25+ and CD25− Subpopulations1 , 2000, The Journal of Immunology.
[40] J. D. White,et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] A. Enk,et al. Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood , 2001, The Journal of experimental medicine.